A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19
Status:
Completed
Trial end date:
2023-02-06
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy of post-exposure prevention and safety of HH-120 nasal
spray in participants who are caregivers of hospitalized patients infected with SARS-CoV-2.
HH-120 nasal spray are administrated 8-10 times to the participants per day until the
discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant,
whichever occurs first.